{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
beta carotene
to a specific field?
Class (Stereo):
CHEMICAL (ABSOLUTE)
Oxetacillin was developed as an antibacterial drug that has never been marketed.
Class (Stereo):
CHEMICAL (UNKNOWN)
Class (Stereo):
CHEMICAL (RACEMIC)
Penirolol is a beta-adrenergic blocking agent that was studied as an antihypertensive agent. Information about the further development of this drug is not available.
Status:
Investigational
Source:
INN:ruboxistaurin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Ruboxistaurin is an orally bioavailable, selective, potent inhibitor of protein kinase C β developed for treating diabetic retinopathy. In vitro and in vivo non-clinical models have demonstrated that Ruboxistaurin decreases PKC β activity and ameliorates many of the effects of PKC β on pathologic processes in the retina. Ruboxistaurin prevents the slowing of retinal blood flow that is observed by fluorescein video angiography in the eyes of diabetic rats. It is also reported to cause regression of retinal neovascularization produced by laser-induced major branch vein occlusions in a porcine model. Ruboxistaurin positively affected the diabetes-induced retinal blood flow abnormalities in a Phase Ib study in diabetic patients. Ruboxistaurin is in phase III clinical trials for the treatment of diabetic nephropathy and diabetic macular edema. Eli Lilly had submitted Ruboxistaurin for approval in the US and the EU; however, the company subsequently discontinued development as it was unable to demonstrate sufficient efficacy
Status:
Investigational
Source:
INN:iodofiltic acid (¹²³I) [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Iodofiltic Acid I-123 is a single-photon branching free fatty acid radiopharmaceutical with potential application in single-photon emission computed tomography (SPECT). Assessment of fatty acid metabolism by radionuclide techniques has a potential role for the early detection of myocardial ischaemia and the assessment of the severity of ischaemic heart disease. The Iodofiltic Acid I-123 scan is preferable because it can provide suitable information for risk stratification just after an acute myocardial infarction (AMI) without requiring the patient to exercise; it can also detect previous ischaemic insult even after recovery of myocardial perfusion, the so- called "ischaemic memory".
Class (Stereo):
CHEMICAL (RACEMIC)
ISOXAPROLOL is a potent beta-adrenoceptor antagonist with antihypertensive properties. It was effective in lowering blood pressure in acute trials on spontaneously hypertensive rats at a dosage of 15 mg/kg.
Class (Stereo):
CHEMICAL (EPIMERIC)
Fenbenicillin (phenoxybenzylpenicillin) is an acid-stable, orally active penicillin. Fenbenicillin demonstrated antibacterial activity in patients suffering from streptococcal, pneumococcal,
and penicillin-sensitive staphylococcal infections.
Class (Stereo):
CHEMICAL (RACEMIC)
Pentorex (Modatrop) is phenylisopropylamine derivative. It is a central adrenergic stimulant drug related to phentermine, which is used as an anorectic to assist with weight loss. Pentorex is sympathomimetic agent.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Acebrochol is a neuroactive steroid that may act as a sedative and hypnotic, through the mechanism of altering ligand-gated ion channels and cell surface receptors.
Status:
Investigational
Source:
NCT00844922: Phase 2 Interventional Completed Depressive Disorders
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
ORG-34517 (or PT 150), a glucocorticoid receptor antagonist was development by Organon for the treatment of depression. This drug has completed phase II clinical trial for patients with major depression with psychotic features, however, this study was discontinued. In addition, Pop Test Cortisol LLC is developing ORG-34517 for the treatment of alcoholism. Now, this drug is in phase I clinical trial on stage recruiting to evaluate its safety when it is taken concurrently with alcohol.
